Amarin drug will struggle against generics, says Summer Street

theflyonthewall.com

Summer Street thinks Amarin's (AMRN) fish oil product Vascepa will struggle to compete against generic versions of GlaxoSmithKline’s (GSK) Lovaza unless Vascepa shows a reduction in cardiovascular events in the REDUCE-IT trial, which is scheduled to complete no earlier than 2016. Further, Summer Street doubts Amarin's Vascepa will be approved as a treatment of moderate triglycerides later this year. Recall that yesterday, an appeals court cleared the way for generic Lovaza by ruling against GSK.

View Comments (3)